{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:49:26Z","timestamp":1786121366843,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008047","name":"Hebei University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017587","name":"Hebei University of Engineering","doi-asserted-by":"publisher","award":["SJ2401002220"],"award-info":[{"award-number":["SJ2401002220"]}],"id":[{"id":"10.13039\/501100017587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neuropharm.2026.111111","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:36:01Z","timestamp":1784129761000},"page":"111111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enavogliflozin alleviates motor deficits in rotenone-induced Parkinson's disease mice via attenuation of oxidative stress and neuroinflammation as well as activation of the SIRT1\/PINK1\/Parkin pathway"],"prefix":"10.1016","volume":"299","author":[{"given":"Tengfei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5699-8581","authenticated-orcid":false,"given":"Hexin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111111_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113839","article-title":"Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats","volume":"146","author":"Abdelaziz","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111111_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.70069","article-title":"SIRT1 in aging and diseases","volume":"126","author":"Abdulkhaliq","year":"2025","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson's Disease rat model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111111_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","article-title":"Parkin and PINK1 functions in oxidative stress and neurodegeneration","volume":"133","author":"Barodia","year":"2017","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 pathway in Parkinson's disease: a faraway snapshot but so close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111111_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/240146","article-title":"Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems","volume":"2012","author":"Cacciatore","year":"2012","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2026.111111_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111404","article-title":"Vitexin alleviates cerebral ischemia\/reperfusion injury by regulating mitophagy via the SIRT1\/PINK1\/Parkin pathway","volume":"227","author":"Chen","year":"2025","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41531-025-00892-6","article-title":"SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4\/NF-\u03baB-mediated neuroinflammation via gut microbiota","volume":"11","author":"Chen","year":"2025","journal-title":"npj Parkinson's Dis."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib9","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/ijms21072464","article-title":"Historical perspective: models of Parkinson's Disease","volume":"21","author":"Chia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111111_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/pharmaceutics12030268","article-title":"Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin","volume":"12","author":"Choi","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111111_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrn3039","article-title":"Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates","volume":"12","author":"Collier","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib12","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/brain\/awad064","article-title":"Impaired dopamine release in Parkinson's disease","volume":"146","author":"Cramb","year":"2023","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110672","article-title":"Glucose metabolism impairment in Parkinson's disease","volume":"199","author":"Dai","year":"2023","journal-title":"Brain Res. Bull."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s11064-016-1901-5","article-title":"Vanillin attenuated behavioural impairments, neurochemical deficts, oxidative stress and apoptosis against rotenone induced rat model of Parkinson's Disease","volume":"41","author":"Dhanalakshmi","year":"2016","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson's disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2026.111111_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101263","article-title":"Oxidative stress and regulated cell death in Parkinson's disease","volume":"67","author":"Dion\u00edsio","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102816","article-title":"Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: a systematic review and meta-analysis","volume":"17","author":"Dutta","year":"2023","journal-title":"Diabetes Metabol. Syndr."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111111_bib18","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/medicina60101682","article-title":"Targeting the Sirtuin-1\/PPAR-Gamma axis, RAGE\/HMGB1\/NF-\u03baB signaling, and the mitochondrial functions by Canagliflozin augments the protective effects of Levodopa\/Carbidopa in rotenone-induced Parkinson's Disease","volume":"60","author":"Elkady","year":"2024","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41401-021-00713-5","article-title":"Age-dependent alterations in key components of the nigrostriatal dopaminergic system and distinct motor phenotypes","volume":"43","author":"Fan","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2026.111111_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fneur.2017.00527","article-title":"Mitophagy in Parkinson's Disease: pathogenic and therapeutic implications","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.178831","article-title":"Empagliflozin halts NLRP3 inflammasome-mediated neurodegeneration in Parkinson's Disease in a rotenone rat model","volume":"1021","author":"Ghaith","year":"2026","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114797","article-title":"Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons","volume":"14","author":"Giehrl-Schwab","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2026.111111_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.dib.2015.12.012","article-title":"Data supporting the spectrophotometric method for the estimation of catalase activity","volume":"6","author":"Hadwan","year":"2015","journal-title":"Data Brief"},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib25","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948686","article-title":"PINK1 phosphorylates Drp1S616 to regulate mitophagy-independent mitochondrial dynamics","volume":"21","author":"Han","year":"2020","journal-title":"EMBO Rep."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/acel.70101","article-title":"SGLT2 inhibition by Enavogliflozin significantly reduces A\u03b2 pathology and restores cognitive function via upregulation of microglial AMPK signaling in 5XFAD mouse model of Alzheimer's Disease","volume":"24","author":"Han","year":"2025","journal-title":"Aging Cell"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2026.111111_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1568002","article-title":"Galangin reduces MPTP-induced dopamine neuron injury via the autophagy dependent-PI3K\/AKT pathway","volume":"17","author":"Huang","year":"2025","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.14336\/AD.2021.0517","article-title":"Adeno-associated virus expression of \u03b1-Synuclein as a tool to model Parkinson's Disease: current understanding and knowledge gaps","volume":"12","author":"Huntington","year":"2021","journal-title":"Aging and disease"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib30","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acs.chemrestox.0c00522","article-title":"Using rotenone to model Parkinson's Disease in mice: a review of the role of pharmacokinetics","volume":"34","author":"Innos","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/cells12071012","article-title":"Microglia mediated neuroinflammation in Parkinson's Disease","volume":"12","author":"Isik","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00204-024-03696-4","article-title":"Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants","volume":"98","author":"Jomova","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2013.01.032","article-title":"Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats","volume":"236","author":"Karuppagounder","year":"2013","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12974-017-0871-0","article-title":"Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity","volume":"14","author":"Kirkley","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111111_bib35","article-title":"Is disrupted mitophagy a central player to Parkinson's Disease pathology?","volume":"15","author":"Ko","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111111_bib36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12640-017-9770-5","article-title":"Treadmill exercise attenuates \u03b1-Synuclein levels by promoting mitochondrial function and autophagy possibly via SIRT1 in the chronic MPTP\/P-Induced mouse model of Parkinson's Disease","volume":"32","author":"Koo","year":"2017","journal-title":"Neurotox. Res."},{"issue":"7503","key":"10.1016\/j.neuropharm.2026.111111_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nature13392","article-title":"Ubiquitin is phosphorylated by PINK1 to activate parkin","volume":"510","author":"Koyano","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111111_bib38","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180249","article-title":"Protein damage, ageing and age-related diseases","volume":"9","author":"Krisko","year":"2019","journal-title":"Open Biol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib39","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/dom.15046","article-title":"Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial","volume":"25","author":"Kwak","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111111_bib40","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1007\/s11010-025-05358-0","article-title":"Sirtuins in mitophagy: key gatekeepers of mitochondrial quality","volume":"480","author":"Lagunas-Rangel","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2026.111111_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176819","article-title":"Experimental models of Parkinson's disease: challenges and opportunities","volume":"980","author":"Lal","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neubiorev.2014.04.001","article-title":"Aging and motor inhibition: a converging perspective provided by brain stimulation and imaging approaches","volume":"43","author":"Levin","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2026.111111_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101817","article-title":"PINK1\/Parkin-mediated mitophagy in neurodegenerative diseases","volume":"84","author":"Li","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12264-024-01342-8","article-title":"Type 2 diabetes mellitus exacerbates pathological processes of Parkinson's Disease: insights from signaling pathways mediated by insulin receptors","volume":"41","author":"Liu","year":"2025","journal-title":"Neurosci. Bull."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib45","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bcp.2007.07.007","article-title":"Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose","volume":"74","author":"Lu","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111111_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.168074","article-title":"SIRT1-PINK1-Parkin axis orchestrated mitophagy and renal repair by dapagliflozin in diabetic nephropathy","volume":"1872","author":"Ma","year":"2026","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2026.111111_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ceb.2017.03.013","article-title":"PINK1 and Parkin: emerging themes in mitochondrial homeostasis","volume":"45","author":"McWilliams","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10787-023-01384-w","article-title":"Empagliflozin repurposing in Parkinson's disease; modulation of oxidative stress, neuroinflammation, AMPK\/SIRT-1\/PGC-1\u03b1, and wnt\/\u03b2-catenin pathways","volume":"32","author":"Mohammed","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111111_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2013.10.009","article-title":"Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress","volume":"77","author":"Moisoi","year":"2014","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib50","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","article-title":"Mitochondrial dysfunction and Parkinson's Disease: pathogenesis and therapeutic strategies","volume":"48","author":"Moradi Vastegani","year":"2023","journal-title":"Neurochem. Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111111_bib51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tcb.2016.05.008","article-title":"Deciphering the molecular signals of PINK1\/Parkin mitophagy","volume":"26","author":"Nguyen","year":"2016","journal-title":"Trends Cell Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111111_bib52","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1007\/s12035-015-9337-5","article-title":"Oxidative stress in neurodegenerative diseases","volume":"53","author":"Niedzielska","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111111_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101979","article-title":"Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease","volume":"89","author":"Nowell","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2026.111111_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117623","article-title":"Cajanus cajan (L) Millsp seeds extract prevents rotenone-induced motor- and non-motor features of Parkinson disease in mice: insight into mechanisms of neuroprotection","volume":"322","author":"Olubodun-Obadun","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111111_bib56","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson's Disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib57","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuint.2010.12.016","article-title":"Mitochondrial dysfunction in brain aging: role of oxidative stress and cardiolipin","volume":"58","author":"Paradies","year":"2011","journal-title":"Neurochem. Int."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111111_bib58","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/biom11101508","article-title":"Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson's Disease: roads to biomarker discovery","volume":"11","author":"Picca","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","article-title":"Oxidative stress and cellular pathologies in Parkinson's disease","volume":"10","author":"Puspita","year":"2017","journal-title":"Mol. Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-020-01062-w","article-title":"PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation","volume":"8","author":"Quinn","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5114\/fn.2019.89857","article-title":"Rotenone: from modelling to implication in Parkinson's disease","volume":"57","author":"Radad","year":"2019","journal-title":"Folia Neuropathol."},{"issue":"6301","key":"10.1016\/j.neuropharm.2026.111111_bib62","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.neuropharm.2026.111111_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1088957","article-title":"Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease","volume":"14","author":"Ruan","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib64","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s12035-023-03359-y","article-title":"Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a mechanistic approach","volume":"60","author":"Sabari","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12868-017-0364-1","article-title":"SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson's disease","volume":"18","author":"Singh","year":"2017","journal-title":"BMC Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib66","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s10753-020-01242-9","article-title":"Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation","volume":"43","author":"Singh","year":"2020","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111111_bib67","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/dom.15537","article-title":"A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study","volume":"26","author":"Sohn","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib68","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00702-025-02882-7","article-title":"Impact of diabetes mellitus type two on incidence and progression of Parkinson's disease: a systematic review of longitudinal patient cohorts","volume":"132","author":"Stockmann","year":"2025","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2026.111111_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111111_bib70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.neuropharm.2026.111111_bib71","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3390\/cells13221876","article-title":"Targeting glucose metabolism: a novel therapeutic approach for Parkinson's Disease","volume":"13","author":"Tanvir","year":"2024","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111111_bib72","first-page":"441","article-title":"miRNA-384-5p regulates the progression of Parkinson's disease by targeting SIRT1 in mice and SH-SY5Y cell","volume":"45","author":"Tao","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111111_bib73","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/ijms23031845","article-title":"The anxiolytic drug buspirone prevents rotenone-induced toxicity in a mouse model of Parkinson's Disease","volume":"23","author":"Thomas Broome","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111111_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023660","article-title":"Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B","volume":"6","author":"Tran","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111111_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13031","article-title":"Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease","volume":"18","author":"Trist","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuropharm.2026.111111_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ab.2016.10.021","article-title":"Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges","volume":"524","author":"Tsikas","year":"2017","journal-title":"Anal. Biochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111111_bib77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/10715762.2017.1315114","article-title":"In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer's disease, Parkinson's disease, and diabetes","volume":"51","author":"Umeno","year":"2017","journal-title":"Free Radic. Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111111_bib78","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3390\/cells10113022","article-title":"Disruption of mitochondrial homeostasis: the role of PINK1 in Parkinson's Disease","volume":"10","author":"Vizziello","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111111_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13034","article-title":"PINK1-mediated mitophagy maintains pluripotency through optineurin","volume":"54","author":"Wang","year":"2021","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111111_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cbin.10864","article-title":"SIRT1 mediates salidroside-elicited protective effects against MPP+ -induced apoptosis and oxidative stress in SH-SY5Y cells: involvement in suppressing MAPK pathways","volume":"42","author":"Wang","year":"2018","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.neuropharm.2026.111111_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102667","article-title":"Oxidative stress and mitochondrial impairment: key drivers in neurodegenerative disorders","volume":"104","author":"Wen","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"8055","key":"10.1016\/j.neuropharm.2026.111111_bib82","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-025-08590-2","article-title":"Dual regulation of mitochondrial fusion by Parkin-PINK1 and OMA1","volume":"639","author":"Yamada","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111111_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108627","article-title":"Parecoxib alleviates the motor behavioral decline of aged rats by ameliorating mitochondrial dysfunction in the substantia nigra via COX-2\/PGE2 pathway inhibition","volume":"194","author":"Yan","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111111_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110217","article-title":"Mitochondrial DAMPs: key mediators in neuroinflammation and neurodegenerative disease pathogenesis","volume":"264","author":"Yu","year":"2025","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2026.111111_bib85","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/aps.2017.49","article-title":"Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"20","key":"10.1016\/j.neuropharm.2026.111111_bib86","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.3390\/ijerph16203811","article-title":"Involvement of Akt\/mTOR in the neurotoxicity of rotenone-induced Parkinson's Disease models","volume":"16","author":"Zhang","year":"2019","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.neuropharm.2026.111111_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2018.10.025","article-title":"Loss of PINK1 causes age-dependent decrease of dopamine release and mitochondrial dysfunction","volume":"75","author":"Zhi","year":"2019","journal-title":"Neurobiol. Aging"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:26:09Z","timestamp":1786076769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826002868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":87,"alternative-id":["S0028390826002868"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111111","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enavogliflozin alleviates motor deficits in rotenone-induced Parkinson's disease mice via attenuation of oxidative stress and neuroinflammation as well as activation of the SIRT1\/PINK1\/Parkin pathway","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111111"}}